---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-025650"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:24:47.098453+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Monopar reports Q2 net loss $1.7M, initiates 1-for-5 reverse split to regain Nasdaq compliance

## Summary
- Net loss for Q2 2024 was $1.7M ($0.10/sh) vs $2.2M ($0.16/sh) in Q2 2023; cash $7.1M sufficient through Aug 31, 2025.
- MNPR-101-Zr Phase 1 imaging trial initiated and enrolling; MNPR-101-RIT therapeutic trial on track to start Q4 2024.
- 1-for-5 reverse stock split effective Aug 12, 2024; shares reduce from ~17.6M to ~3.5M to regain Nasdaq compliance.
- Company winding down camsirubicin and MNPR-202 programs to focus on radiopharmaceutical platform.
- Needs additional funding within 12 months to further advance radiopharma programs.

## SEC filing metadata
- accession: 0001437749-24-025650
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 3.03, 5.03, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924025650/0001437749-24-025650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924025650/mnpr20240807_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-025650
- JSON: https://secwatch.observer/filing/0001437749-24-025650.json
- Plain text: https://secwatch.observer/filing/0001437749-24-025650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.